Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MGX
- Price
- 1.45
- Stock movement up
- +- (%)
- Company name
- Metagenomi, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 69.44M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -41.27%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MGX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.82 |
| Daily high | 1.92 |
| Daily low | 1.81 |
| Daily Volume | 133K |
| All-time high | 12.25 |
| 1y analyst estimate | 9.50 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 Nov 2025 |
Downside potential
Loading...
Downside potential data
| MGX | S&P500 | |
| Current price drop from All-time high | -84.90% | -1.46% |
| Highest price drop | -89.71% | -56.47% |
| Date of highest drop | 3 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -67.50% | -10.99% |
| Avg time to new high | 77 days | 12 days |
| Max time to new high | 381 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
69.44M
Marketcap category
Small-cap
Description
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Employees
171
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page